Albemarle Secures DOE Grant for U.S.-Based Lithium Facility to Support Domestic EV Supply Chain

PR Newswire


CHARLOTTE, N.C.
, Oct. 19, 2022 /PRNewswire/ — Albemarle Corporation (NYSE: ALB), a global leader in the specialty chemicals industry, announced it has been awarded a nearly $150 million grant from the U.S. Department of Energy (DOE) as part of the first set of projects funded by the President’s Bipartisan Infrastructure Law to expand domestic manufacturing of batteries for electric vehicles (EVs) and the electrical grid and for materials and components currently imported from other countries. The grant funding is intended to support a portion of the anticipated cost to construct a new, commercial-scale U.S.-based lithium concentrator facility at Albemarle’sKings Mountain, North Carolina, location.

Albemarle CEO Kent Masters will participate in today’s virtual White House event as part of the DOE award recipient announcement, reiterating Albemarle’s commitment to invest in the U.S. to source and process the critical materials used to make lithium-ion batteries.

Albemarle is proud to partner with the federal government to bring manufacturing jobs to the southeastern United States, strengthening the domestic supply chain for the growing electric vehicle market. Receiving the DOE grant affirms Albemarle’s position as a global market leader and one of the only lithium companies currently producing battery-grade lithium from U.S. resources,” said Masters. “Expanding our U.S. footprint also increases the speed of lithium processing and reduces greenhouse gas emissions from long-distance transportation of raw minerals. We hope this project spurs additional investment by others in the domestic EV battery supply chain, such as cathode manufacturers, battery makers, and auto manufacturers.”

Albemarle expects the concentrator facility to create hundreds of construction and full-time jobs, and to supply up to 350,000 metric tons per year of spodumene concentrate to the company’s previously announced mega-flex lithium conversion facility. The mega-flex conversion facility is expected to eventually produce up to 100,000 metric tons of battery-grade lithium per year to support domestic manufacturing of up to 1.6 million EVs per year. Albemarle is finalizing the site selection for the mega-flex conversion facility in the southeastern United States. That facility design would accommodate multiple feedstocks, including spodumene from the proposed reopening of the company’s hard rock mine in Kings Mountain; its existing lithium brine resources in Silver Peak, Nevada, and other global resources; as well as potential recycled lithium materials from existing batteries.

In addition to supporting the development of the concentrator, Albemarle will use a portion of the grant to support a $5 million mineral processing operator training program at Cleveland Community College, a $1.5 million minerals lab research program at Virginia Tech, and a $1.5 million minerals pilot plant and engineering training program at North Carolina State University’s Asheville Minerals Research Lab.

Development of both the lithium concentrator and the mega-flex conversion facility, the proposed reopening of the Kings Mountain mine, and an active expansion of the Silver Peak facility are part of a larger Albemarle strategy to invest in the U.S. EV battery supply chain.

About Albemarle Corporation

Albemarle Corporation (NYSE: ALB) is a global specialty chemicals company with leading positions in lithium, bromine and catalysts. We think beyond business as usual to power the potential of companies in many of the world’s largest and most critical industries, such as energy, electronics, and transportation. We actively pursue a sustainable approach to managing our diverse global footprint of world-class resources. In conjunction with our highly experienced and talented global teams, our deep-seated values, and our collaborative customer relationships, we create value-added and performance-based solutions that enable a safer and more sustainable future.

We regularly post information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, SEC filings and other information regarding our company, our businesses and the markets we serve.

Forward-Looking Statements

Some of the information presented in this press release, including, without limitation, information related to the timing and transition to, and the benefits of, receipt of funds from the DOE grant, the expected costs, specifications and production capabilities of the planned Kings Mountain concentrator facility and the mega-flex conversion facility, and the number of jobs and educational programs created by Albemarle’s facilities and grants, and including all information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the views expressed. Factors that could cause Albemarle’s actual results to differ materially from the outlook expressed or implied in any forward-looking statement include, without limitation: changes to or delays in the application of the Bipartisan Infrastructure Law and funds authorized thereunder due to political disagreement, legislative processes or other factors; changes in economic and business conditions; changes in financial and operating performance of its major customers and industries and markets served by it; the timing of orders received from customers; the gain or loss of significant customers; fluctuations in lithium market pricing, which could impact our revenues and profitability particularly due to our increased exposure to index-referenced and variable-priced contracts for battery grade lithium sales; changes with respect to contract renegotiations; potential production volume shortfalls; competition from other manufacturers; changes in the demand for its products or the end-user markets in which its products are sold; limitations or prohibitions on the manufacture and sale of its products; availability of raw materials; increases in the cost of raw materials and energy, and its ability to pass through such increases to its customers; technological change and development, changes in its markets in general; fluctuations in foreign currencies; changes in laws and government regulation impacting its operations or its products; the occurrence of regulatory actions, proceedings, claims or litigation (including with respect to the U.S. Foreign Corrupt Practices Act and foreign anti-corruption laws); the occurrence of cyber-security breaches, terrorist attacks, industrial accidents or natural disasters; the effect of climate change, including any regulatory changes to which it might be subject; hazards associated with chemicals manufacturing; the inability to maintain current levels of insurance, including product or premises liability insurance, or the denial of such coverage; political unrest affecting the global economy, including adverse effects from terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from its global manufacturing cost reduction initiatives as well as its ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of its earnings and changes in tax laws and rates or interpretation; changes in monetary policies, inflation or interest rates that may impact its ability to raise capital or increase its cost of funds, impact the performance of its pension fund investments and increase its pension expense and funding obligations; volatility and uncertainties in the debt and equity markets; technology or intellectual property infringement, including cyber-security breaches, and other innovation risks; decisions it may make in the future; future acquisition and divestiture transactions, including the ability to successfully execute, operate and integrate acquisitions and divestitures and incurring additional indebtedness; continuing uncertainties as to the duration and impact of the coronavirus (COVID-19) pandemic; performance of Albemarle’s partners in joint ventures and other projects; changes in credit ratings; and the other factors detailed from time to time in the reports Albemarle files with the SEC, including those described under “Risk Factors” in Albemarle’s most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release. Albemarle assumes no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/albemarle-secures-doe-grant-for-us-based-lithium-facility-to-support-domestic-ev-supply-chain-301653808.html

SOURCE Albemarle Corporation

Pure Storage Named a Leader in the 2022 Gartner® Magic Quadrant™ for Primary Storage

PR Newswire

Latest recognition marks ninth consecutive year of Pure Storage’s position as a Gartner Magic Quadrant Leader


MOUNTAIN VIEW, Calif.
, Oct. 19, 2022 /PRNewswire/ — Pure Storage® (NYSE: PSTG), the IT pioneer that delivers the world’s most advanced data storage technology and services, today announced it has been positioned by Gartner as a Leader in the Magic Quadrant for Primary Storage. This marks the ninth1 consecutive year of recognition in the Magic Quadrant for Pure Storage. This is also the third consecutive year that Pure Storage has been positioned highest on the Ability to Execute axis and furthest on the Completeness of Vision axis, which we believe validates its leadership across the enterprise storage industry.

Pure Storage’s FlashArray™ product line began as a pioneering all-flash storage array built for high performance block storage-based applications. Since then, it has expanded beyond block to also include file storage use cases from a single array without losing any of the performance, ease of use and reliability that has become synonymous with Pure Storage.

The current FlashArray family includes the performance-optimized FlashArray//X™ and FlashArray//XL™ models, built to handle the most data intensive workloads at almost any level of scale; the QLC-based FlashArray//C™, which is rapidly making hybrid and disk-based storage arrays obsolete from a price and performance standpoint; Pure Cloud Block Store, a cloud-based, data services-rich offering allowing enterprises to confidently run business critical application in Microsoft Azure and AWS; and most recently, Pure Fusion™, a SaaS control plane enabling customers to transform storage arrays into an autonomous storage-as-code platform providing cloud-like self-service for end users. The full portfolio of products is now underpinned by Pure Storage’s AIOps platform in Pure1®.

“We believe Pure has become the clear leader in disrupting the storage industry,” said Shawn Hansen, VP and General Manager, FlashArray, Pure Storage. “We led with the first designed-for-flash enterprise array and as-a-service business models. Now as we’ve unveiled the industry’s first self-service, storage-as-code product, the market is entering the next stage of rapid change as it speeds towards the simplicity and automation of a cloud operating model, everywhere.”

FlashArray has achieved several milestones over the past year, including:

  • Introduction of FlashArray//XL: The newest member of the FlashArray family, FlashArray//XL is designed for mission-critical, platinum tier enterprise applications – from massive databases to containerized and cloud-native apps. FlashArray//XL delivers unmatched performance and scale with a nearly 80% improvement in IOPS.
  • General Availability of Pure Fusion:

    Pure Fusion
    is now generally available, offering not just a self-service provisioning user experience but also a Storage-as-Code experience that enables developers to tap into even faster provisioning and the autonomous backend to support cloud scale.
  • Heightened Data Security with the release of Purity//FA 6.3: the latest Purity//FA release delivers always on data protection for enterprises everywhere. Auto-on SafeMode™ Snapshots adds protection that is on by default, providing immutable protection, without the need to change an organization’s existing setup, environment, or processes.
  • Impact on Enterprise Sustainability: The FlashArray family supports enterprises’ most strategic sustainability initiatives, helping customers to dramatically reduce their energy use and environmental footprint. With FlashArray products, customers can achieve up to 84.7% in direct energy savings compared to competing solutions.

Magic Quadrant™ reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables organizations to get the most from market analysis in alignment with their unique business and technology needs.

To learn more, access the full 2022 Gartner 2022 Magic Quadrant for Primary Storage report on Pure Storage’s website.

Additional resources:

Gartner Disclaimer
GARTNER and Magic Quadrant are a registered trademark and service mark, and PEER INSIGHTS is a trademark and service mark, of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Pure Storage
Pure Storage (NYSE: PSTG) uncomplicates data storage, forever. Pure delivers a cloud experience that empowers every organization to get the most from their data while reducing the complexity and expense of managing the infrastructure behind it. Pure’s commitment to providing true storage as-a-service gives customers the agility to meet changing data needs at speed and scale, whether they are deploying traditional workloads, modern applications, containers, or more. Pure believes it can make a significant impact in reducing data center emissions worldwide through its environmental sustainability efforts, including designing products and solutions that enable customers to reduce their carbon and energy footprint. And with a certified customer satisfaction score in the top one percent of B2B companies, Pure’s ever-expanding list of customers are among the happiest in the world. For more information, visit www.purestorage.com.

Pure Storage, the Pure Storage P Logo, Pure1, Pure Fusion, FlashArray, FlashArray//C, FlashArray//X, FlashArray//XL, and SafeMode are trademarks or registered trademarks of Pure Storage Inc. in the U.S. and/or other countries. The Pure Storage Inc. Trademark List can be found at www.purestorage.com/legal/productenduserinfo.html.

Analyst Recognition: 


Leader in the
2022
 Gartner Magic Quadrant for Primary Storage



Leader in the 2021 Gartner Magic Quadrant for Distributed File Systems & Object Storage

Connect with Pure 


Blog



LinkedIn



Twitter



Facebook


1
 This includes five years as a Leader in the Magic Quadrant for Solid-State Arrays and now four years as a Leader in the Magic Quadrant for Primary Storage

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pure-storage-named-a-leader-in-the-2022-gartner-magic-quadrant-for-primary-storage-301653768.html

SOURCE Pure Storage

Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union

NEW YORK and MAINZ, Germany, October 19, 2022Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization (MA) for a 3-µg dose of COMIRNATY® (COVID-19 vaccine, mRNA), which is based on the wild-type spike protein of SARS-CoV-2, as a three-dose series for children ages 6 months to less than 5 years (also referred to as 6 months through 4 years of age). The European Commission will review the CHMP recommendation and is expected to make a final decision soon.

Today’s recommendation is based on data from a Phase 2/3 randomized, controlled trial that included 4,526 children aged 6 months to less than 5 years. In the trial, children received a third 3-µg dose of the original Pfizer-BioNTech COVID-19 Vaccine at least two months after the second dose at a time when Omicron BA.2 was the predominant variant. Following the third dose in this age group, the companies’ original COVID-19 vaccine was found to be 73.2% (2-sided 95% CI: 43.8%, 87.6%) effective at preventing COVID-19, with a favorable safety profile similar to placebo. The 3-µg dose was carefully selected as the preferred dose for children under 5 years of age based on safety, tolerability, and immunogenicity.

The U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) of the original Pfizer-BioNTech COVID-19 Vaccine as a three 3-µg dose series in this age group in June 2022. Submissions to other regulatory agencies around the world are ongoing.

Pfizer and BioNTech are also in discussions with health authorities regarding a regulatory pathway for potential authorization of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for use in children under 5 years of age. A Phase 1/2/3 pediatric study was initiated in September 2022 to evaluate different dosing regimens and dose levels of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine across age groups.

COMIRNATY® and its adapted vaccine variations (COMIRNATY® Original/Omicron BA.1 and COMIRNATY® Original/Omicron BA.4-5) are based on BioNTech’s proprietary mRNA technology and were developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.


About the Phase 1/2/3 Trial in Children for the Original Pfizer-BioNTech COVID-19 Vaccine


The Phase 1/2/3 trial (NCT04816643) has enrolled more than 10,000 children ages 6 months to under 12 years of age in the United States, Finland, Poland, Spain and Brazil from more than 90 clinical trial sites. The trial evaluated the safety, tolerability, and immunogenicity of the original Pfizer-BioNTech COVID-19 Vaccine in three age groups: ages 5 to less than12 years; ages 2 to less than 5 years; and ages 6 months to less than 2 years. Based on the Phase 1 dose-escalation portion of the trial, children ages 5 to less than 12 years received a two-dose schedule of 10 µg each while children under age 5 received three lower 3-µg doses in the Phase 2/3 study. The trial enrolled children with or without prior evidence of SARS-CoV-2 infection.


AUTHORIZED USE IN THE EU:


COMIRNATY® ▼ (the Pfizer-BioNTech COVID-19 vaccine) has been granted standard marketing authorization (MA) by the European Commission to prevent coronavirus disease 2019 (COVID-19) in people aged 5 years and older. The vaccine is administered as a 2-dose series, 3 weeks apart. Adults and adolescents from the age of 12 are given 30 micrograms per dose; children aged 5 to 11 years are given 10 micrograms per dose. In addition, the MA has been expanded to include a booster dose (third dose) at least 3 months after the second dose in individuals 12 years of age and older. A third primary course dose may be administered at least 28 days after the second dose to people aged 5 years and older with a severely weakened immune system. The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has completed its rigorous evaluation of COMIRNATY, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available.
In addition, COMIRNATY has also been granted standard MA for two adapted vaccines: COMIRNATY Original/Omicron BA.1, which contains mRNA encoding for the spike protein of the wild-type and of the Omicron BA.1 subvariant of SARS-CoV-2; and COMIRNATY Original/Omicron BA.4-5, which contains mRNA encoding for the spike protein of the wild-type and of the Omicron BA.4/BA.5 subvariant of SARS-CoV-2. COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 may be administered as a booster in people aged 12 years and older who have received at least a primary vaccination course against COVID-19. There should be an interval of at least 3 months between administration of COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 and the last prior dose of a COVID-19 vaccine.


IMPORTANT SAFETY INFORMATION:

  • Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.
  • There is an increased, but very rare risk (<1/10,000 cases) of myocarditis and pericarditis following vaccination with COMIRNATY. These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general. The risk of myocarditis after a booster dose of COMIRNATY, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 has not yet been characterized.
  • Rare cases of acute peripheral facial paralysis; uncommon incidence of insomnia, hyperhidrosis and night sweats; and unknown incidence of paraesthesia, hypoaesthesia and erythema multiforme have been identified in post-marketing experience.
  • Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress‐related reactions (e. g. dizziness, palpitations, increases in heart rate, alterations in blood pressure, tingling sensations and sweating) may occur in association with the vaccination process itself. Stress-related reactions are temporary and resolve on their own. Individuals should be advised to bring symptoms to the attention of the vaccination provider for evaluation. It is important that precautions are in place to avoid injury from fainting.
  • Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
  • As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
  • The efficacy, safety and immunogenicity of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of COMIRNATY, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 may be lower in immunosuppressed individuals.
  • As with any vaccine, vaccination with COMIRNATY, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of the vaccine.
  • Adverse reactions observed during clinical studies are listed below according to the following frequency categories: Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000).
    • Very common side effects: injection site pain, injection site swelling, tiredness, headache, muscle pain, chills, joint pain, diarrhea, fever
    • Common side effects: injection site redness, nausea, vomiting
    • Uncommon side effects: enlarged lymph nodes (more frequently observed after the booster dose), feeling unwell, arm pain, insomnia, injection site itching, allergic reactions such as rash or itching, feeling weak or lack of energy/sleepy, decreased appetite, excessive sweating, night sweats
    • Rare side effects: temporary one-sided facial drooping, allergic reactions such as hives or swelling of the face
    • Very rare side effects: inflammation of the heart muscle (myocarditis) or inflammation of the lining outside the heart (pericarditis), which can result in breathlessness, palpitations or chest pain, anaphylaxis, extensive swelling of vaccinated limbs; facial swelling, pins and needles/tingling, reduced sense of touch or sensation, a skin reaction that causes red spots or patches on the skin
  • A large amount of observational data from pregnant women vaccinated with the initially approved COMIRNATY vaccine during the second and third trimester have not shown an increase in adverse pregnancy outcomes. While data on pregnancy outcomes following vaccination during the first trimester are presently limited, no increased risk for miscarriage has been seen. COMIRNATY can be used during pregnancy. No effects on the breast-fed newborn/infant are anticipated since the systemic exposure of breast-feeding woman to the initially approved COMIRNATY vaccine is negligible. Observational data from women who were breast-feeding after vaccination have not shown a risk for adverse effects in breast-fed newborns/infants. COMIRNATY can be used during breast-feeding.
  • No data are available yet regarding the use of COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 during pregnancy. Since differences between products are confined to the spike protein sequence, and there are no clinically meaningful differences in reactogenicity between those COMIRNATY variant-adapted vaccines that have been clinically evaluated, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 can be used during pregnancy.
  • No data are available yet regarding the use of COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 during breast-feeding. Observational data from women who were breast-feeding after vaccination with the initially approved COMIRNATY vaccine have not shown a risk for adverse effects in breast-fed newborns/infants. COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 can be used during breast-feeding
  • Interactions with other medicinal products or concomitant administration of COMIRNATY, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 with other vaccines has not been studied.
  • Animal studies with COMIRNATY Original do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
  • The safety of a COMIRNATY Original/Omicron BA.1 booster dose in individuals from 18 to ≤ 55 years of age is extrapolated from safety data from a subset of 315 adults 18 to ≤ 55 years of age who received a booster (fourth dose) of Omicron BA.1 30 µg (monovalent) after completing 3 doses of COMIRNATY. The most frequent adverse reactions in these participants 18 to ≤ 55 years of age were injection site pain (> 70%), fatigue (> 60%), headache (> 40%), myalgia (> 30%), chills (> 30%) and arthralgia (> 20%).
  • In a subset from the Phase 3 study, 305 adults > 55 years of age who had completed 3 doses of COMIRNATY, received a booster of COMIRNATY Original/Omicron BA.1 after receiving Dose 3. The overall safety profile for the COMIRNATY Original/Omicron BA.1 booster (fourth dose) was similar to that seen after the COMIRNATY booster (third dose). The most frequent adverse reactions in participants greater than 55 years of age were injection site pain (> 50%), fatigue (> 40%), headache 69 (> 30%), myalgia (> 20%), chills and arthralgia (> 10%). No new adverse reactions were identified for COMIRNATY Original/Omicron BA.1.
  • The safety of a booster dose of COMIRNATY Original/Omicron BA.4-5 is inferred from safety data for a booster dose of COMIRNATY Original/Omicron BA.1, as well as for a booster dose of COMIRNATY Original.
  • The duration of protection afforded by the vaccine is unknown as it is still being determined by ongoing clinical trials. As with any vaccine, vaccination with Comirnaty Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 may not protect all vaccine recipients
  • For complete information on the safety of COMIRNATY, COMIRNATY Original/Omicron BA.1 and COMIRNATY Original/Omicron BA.4-5, always make reference to the approved Summary of Product Characteristics and Package Leaflet available in all the languages of the European Union on the EMA website.

The black equilateral triangle ▼ denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. Individuals can help by reporting any side effects they may get. Side effects can be reported to [email protected], www.biontech.com or directly to BioNTech using email, telephone +49 6131 9084 0, or via the website.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information contained in this release is as of October 19, 2022. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162b2 mRNA vaccine program, and the Pfizer-BioNTech COVID-19 Vaccine, also known as COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a submission pending with the EMA and a CHMP opinion for a 3-µg dose of COMIRNATY (COVID-19 vaccine, mRNA), which is based on the wild-type spike protein of SARS-CoV-2, as a three-dose series for children ages 6 months to less than 5 years (also referred to as 6 months through 4 years of age, a regulatory pathway for potential authorization of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for use in children under 5 years of age and a Phase 1/2/3 pediatric study of the Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine, qualitative assessments of available data, potential benefits, expectations for clinical trials, potential regulatory submissions, the anticipated timing of data readouts, regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including Phase 1/2/3 or Phase 4 data), including the data discussed in this release for BNT162b2, any monovalent, bivalent or variant-adapted vaccine candidates or any other vaccine candidate in the BNT162 program in any of our studies in pediatrics, adolescents, or adults or real world evidence, including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies, in real world data studies or in larger, more diverse populations following commercialization; the ability of BNT162b2, any monovalent, bivalent or variant-adapted vaccine candidates or any future vaccine to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when submissions to request emergency use or conditional marketing authorizations for BNT162b2 in additional populations, for a potential booster dose for BNT162b2, any monovalent or bivalent vaccine candidates or any potential future vaccines (including potential future annual boosters or re-vaccination), and/or other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2, any monovalent or bivalent vaccine candidates or any other potential vaccines that may arise from the BNT162 program, including a potential variant-based, higher dose, or bivalent vaccine, and if obtained, whether or when such emergency use authorizations or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including any requested amendments to the emergency use or conditional marketing authorizations and the submission pending with the EMA for a 3-µg dose of COMIRNATY (COVID-19 vaccine, mRNA), which is based on the wild-type spike protein of SARS-CoV-2, as a three-dose series for children ages 6 months to less than 5 year), any monovalent or bivalent vaccine candidates, or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist which may lead to reduced revenues or excess inventory; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or potential future annual boosters or re-vaccinations or new variant-based or next generation vaccines; the risk that we may not be able to maintain or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.com.

BioNTech Forward-looking Statements

This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 vaccine, mRNA) (BNT162b2) (including the potential in children 6 months to 5 years of age and a positive CHMP opinion on the administration in children 6 months to 5 years of age in the EU, clinical trials studying the use BNT162b2 and its adapted vaccine variations in children 6 months to 12 years of age, an EUA in the U.S. and a submission pending with the EMA for an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 to less than 12 years of age, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials, real world data studies, and/or in commercial use based on data observations to date; preclinical and clinical data (including Phase 1/2/3 or Phase 4 data), including the descriptive data discussed in this release, for BNT162b2 or any other vaccine candidate in the BNT162 program in any of our studies in pediatrics, adolescents or adults or real world evidence, including the possibility of unfavorable new preclinical, clinical or safety data, including the risk that final or formal results from the clinical trial could differ from the topline data; the ability of BNT162b2 or a future vaccine to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 and its adapted vaccine variations in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; widespread use of BNT162b2 and its adapted vaccine variations will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the timing for submission of data for BNT162, or any future vaccine, in additional populations, (including in children 6 months to less than 5 years of age, potential future annual boosters or re-vaccinations), or receipt of, any marketing approval or emergency use authorization or equivalent, including or amendments or variations to such authorizations, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; the development of other vaccine formulations, booster doses or potential future annual boosters or re-vaccinations or new variant based vaccines; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; the ability of BioNTech to supply the quantities of BNT162 and its adapted vaccine variations to support clinical development and market demand, including our production estimates for 2022; challenges related to public vaccine confidence or awareness; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist which may lead to reduced revenues or excess inventory; the availability of raw material to manufacture BNT162 or other vaccine formulation; challenges related to our vaccine’s formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery; and uncertainties regarding the impact of COVID-19 on BioNTech’s trials, business and general operations. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.

For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report as Form 6-K for the quarter ended June 30, 2022, filed with the SEC on August 8, 2022, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

CONTACTS

Pfizer:

Media Relations
+1 (212) 733-1226
[email protected]

Investor Relations
+1 (212) 733-4848
[email protected]

BioNTech:

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
[email protected]

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
[email protected]



CI Financial Announces Third Quarter Earnings Conference Call and Webcast

CI Financial Announces Third Quarter Earnings Conference Call and Webcast

TORONTO–(BUSINESS WIRE)–
CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX) will release its financial results for the third quarter of fiscal 2022 on Thursday, November 10, 2022.

CI will hold a conference call with analysts that day at 9:00 a.m. EST, led by Chief Executive Officer Kurt MacAlpine and Chief Financial Officer Amit Muni. A live webcast of the call and slide presentation can be accessed here, or through the Investor Relations section of CI’s website.

Alternatively, investors may listen to the discussion through the following numbers (access code: 442598):

  • Canada toll-free: 1-833-950-0062
  • United States toll-free: 1-844-200-6205
  • United States (New York local): 1-646-904-5544
  • All other locations: 1-929-526-1599.

A recording of the webcast will be archived on CI’s Investor Relations site.

About CI Financial

CI Financial Corp. is a diversified global asset and wealth management company operating primarily in Canada, the United States and Australia. Founded in 1965, CI has developed world-class portfolio management talent, extensive capabilities in all aspects of wealth planning, and a comprehensive product suite. CI manages and advises on approximately C$338 billion in client assets (September 30, 2022).

CI operates in three segments:

  • Asset Management, which includes the operations of CI Global Asset Management and Australia-based GSFM Pty Ltd.
  • Canadian Wealth Management, which includes the operations of CI Assante Wealth Management, Aligned Capital Partners, CI Private Wealth (Canada), Northwood Family Office, CI Direct Investing and CI Investment Services.
  • U.S. Wealth Management, which includes CI Private Wealth US, a national network of best-in-class wealth management teams.

CI is headquartered in Toronto and listed on the Toronto Stock Exchange (TSX: CIX) and the New York Stock Exchange (NYSE: CIXX). To learn more, visit CI’s website or LinkedIn page.

This press release contains forward-looking statements concerning anticipated future events, results, circumstances, performance or expectations with respect to CI Financial Corp. (“CI”) and its products and services, including its business operations, strategy and financial performance and condition. Forward-looking statements are typically identified by words such as “believe”, “expect”, “foresee”, “forecast”, “anticipate”, “intend”, “estimate”, “goal”, “plan” and “project” and similar references to future periods, or conditional verbs such as “will”, “may”, “should”, “could” or “would”. These statements are not historical facts but instead represent management beliefs regarding future events, many of which by their nature are inherently uncertain and beyond management’s control. Although management believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements involve risks and uncertainties. The foregoing list is not exhaustive and the reader is cautioned to consider these and other factors carefully and not to place undue reliance on forward-looking statements. Other than as specifically required by applicable law, CI undertakes no obligation to update or alter any forward-looking statement after the date on which it is made, whether to reflect new information, future events or otherwise.

CI Global Asset Management is a registered business name of CI Investments Inc., a wholly owned subsidiary of CI Financial Corp.

Investor Relations

Jason Weyeneth, CFA

Vice-President, Investor Relations & Strategy

416-681-8779

[email protected]

Media Relations

Canada

Murray Oxby

Vice-President, Corporate Communications

416-681-3254

[email protected]

United States

Jimmy Moock

Managing Partner, StreetCred

610-304-4570

[email protected]

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Finance Consulting Banking Professional Services Asset Management

MEDIA:

Logo
Logo

Chegg Announces Appointment of Nathan Schultz as Chief Operating Officer

Chegg Announces Appointment of Nathan Schultz as Chief Operating Officer

In the newly created role, Schultz will oversee all consumer-facing products and services

SANTA CLARA, Calif.–(BUSINESS WIRE)–
Today, Chegg Inc. (NYSE: CHGG) the leading student-first connected learning platform, announced the promotion of Nathan Schultz to Chief Operating Officer, effective immediately. Schultz has served in various roles at Chegg for 15 years, and was previously President of Learning Services, where he was responsible for all aspects of Chegg’s learning tools. Throughout his career, he has successfully overseen Chegg’s required materials service, Chegg Study, Writing, and Math, the creation of the Chegg Study Pack, international growth, and the acquisition and integration of new services such as skills accelerator, Thinkful and language learning service, Busuu.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221019005460/en/

Nathan Schultz, COO Chegg Inc. (Photo: Business Wire)

Nathan Schultz, COO Chegg Inc. (Photo: Business Wire)

In the newly created role, Schultz will drive the expansion and further integration of Chegg’s direct-to-student services including learning services, non-academic support, and career skills training, in order to serve Chegg’s growing user base more effectively and efficiently and ensure a superior holistic consumer experience.

“Nathan has been a transformational leader at our company for many years, and on behalf of myself, his colleagues, and our Board of Directors, we are all delighted he is taking on the role of Chief Operating Officer,” said Dan Rosensweig, CEO and President of Chegg. “Nathan has spent 15 years at Chegg building products that support student learning. He is an industry leader in how to build effective learning tools, and in his new role he will be able to have more impact across the company in how we can best support students and achieve better learning outcomes,” Rosensweig added.

“I am energized and excited to take on this new role. I could not be more grateful to Dan, the Board of Directors, and my colleagues for their support,” said Schultz. “We have an incredible opportunity to bring even more value to our large, global, customer base by bringing together learning services, non-academic support, and skills for students into one offering, to impact and help not just our millions of subscribers, but many more around the world.”

About Chegg

Millions of people all around the world Learn with Chegg. Our mission is to improve learning and learning outcomes by putting students first. We support life-long learners starting with their academic journey and extending into their careers. The Chegg platform provides products and services to support learners to help them better understand their academic course materials, and also provides personal and professional development skills training, to help them achieve their learning goals. Chegg is a publicly held company based in Santa Clara, California and trades on the NYSE under the symbol CHGG. For more information, visit www.chegg.com.

Investor Relations Contact

Tracey Ford, [email protected]

Media Contact

Marc Boxser, [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Internet Continuing Technology University Primary/Secondary Education Training

MEDIA:

Logo
Logo
Photo
Photo
Nathan Schultz, COO Chegg Inc. (Photo: Business Wire)

NOVONIX Selected For US$150 Million Grant From U.S. Department of Energy

– Strategic milestone advancing localization of U.S. battery supply chain –

– Supports NOVONIX’s growth plan to expand synthetic graphite production to 40,000 tonnes per annum in 2025 –

CHATTANOOGA, Tenn., Oct. 19, 2022 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX, OTCQX: NVNXF) (“NOVONIX” or “the Company”), a leading battery materials and technology company, today announced that its NOVONIX Anode Materials division was selected to enter negotiations to receive US$150 million in grant funding from the U.S. Department of Energy (DOE) to expand its domestic production of high-performance, synthetic graphite anode materials. This award, announced by President Biden, strengthens the North American battery supply chain amidst surging demand and growing calls to onshore these critical industries. Negotiations will cover final conditions including operational milestones and timing and schedule of payment of grant funds.

This is the first set of projects funded by President Biden’s Bipartisan Infrastructure Law to expand domestic manufacturing of batteries for electric vehicles and the electrical grid, with a focus on domestic processing of materials and components currently imported from other countries. Responsible and sustainable domestic sourcing and processing of the critical materials used to make lithium-ion batteries will strengthen American supply chains, accelerate battery production to meet increased demand, and secure the nation’s economic competitiveness, energy independence, and national security. 

The funding announced today by the Department of Energy is the first phase of over $7 billion2 in total provided by the President’s Bipartisan Infrastructure Law for the battery supply chain and supports NOVONIX’s execution of its strategic growth plan for synthetic graphite anode materials produced in the U.S. Specifically, the grant funds will be dedicated to the construction of a 30,000 tonnes per annum (tpa) U.S. manufacturing facility, including site selection, plant layout, and engineering design with capability for additional expansion.

DOE’s Office of Manufacturing and Energy Supply Chains (MESC) is responsible for strengthening and securing manufacturing and energy supply chains needed to modernize the nation’s energy infrastructure and support a clean and equitable energy transition. MESC will manage the portfolio of projects with support from DOE’s Office of Energy Efficiency and Renewable Energy’s Vehicle Technologies Office.

“We are proud to have been selected to negotiate this funding in recognition of our readiness to accelerate the domestic battery supply chain and meet growing global demand from the electric vehicle and stationary grid storage markets,” said Dr. Chris Burns, NOVONIX Co-Founder and CEO. “Since inception, our mission has been to enhance batteries through innovation and pave the way for the clean energy transformation. We are excited to partner with the DOE to further our mission of establishing a domestic supply chain for synthetic graphite used in lithium-based batteries and creating long-term sustainable value for our stakeholders.”

The grant is being funded under Area of Interest Two of the recently announced Battery Materials Processing and Battery Manufacturing Funding Opportunity Announcement (FOA), with the main objective of creating battery-grade graphite anode manufacturing capacity in the United States. The Project funded under this award will reduce U.S. reliance on importing this key battery material. China currently dominates both the synthetic and natural graphite markets with 98% and 77% market share, respectively; the rest coming from Japan and Korea1.

Through its proprietary process technology, clean power sources, and strategic partnerships, NOVONIX remains committed to enabling an electrified future while addressing the climate crisis. The Company is on track for reaching annual production capacity of 10,000 tpa of synthetic graphite in 2023 at its existing Riverside facility in Chattanooga, Tennessee, with further plans to expand annual production capacity to 40,000 tpa in 2025 and 150,000 tpa in 2030.

This announcement has been authorized for release by NOVONIX Chairman, Admiral Robert J. Natter, USN Ret.

About NOVONIX

NOVONIX is a leading battery technology company with operations in Canada and the United States. NOVONIX provides advanced high-performance materials, equipment, and services for the global lithium-ion battery industry with sales in 14 countries. We develop materials and technologies to support longer-life and lower-cost batteries that fuel a cleaner energy future.

Our NOVONIX Battery Technology Solutions division, based in Halifax, Nova Scotia, Canada, focuses on innovative battery research and development, along with providing advanced battery testing equipment and services on a global scale.

Our NOVONIX Anode Materials division, located in Chattanooga, Tennessee, USA, manufactures our synthetic graphite anode materials used to make lithium-ion batteries which power electric vehicles, personal electronics, medical devices, and energy storage units. To address growing industry demand, we are working to increase production capacity to 10,000 metric tons of synthetic graphite per annum (tpa) by 2023, with further targets of 40,000 tpa by 2025, and 150,000 tpa by 2030.

To learn more about NOVONIX visit us on LinkedIn, Twitter, or www.novonixgroup.com.


1 Source: Benchmark Mineral Intelligence September 2022 Report



2 Department of Energy (US) May 2, 2022 https://eere-exchange.energy.gov/Default.aspx#FoaId599442c8-d25a-4091-96c0-30c0610a6710



For NOVONIX Limited
Stefan Norbom, [email protected] (investors)
Chantal Theoret, [email protected] (media)

CoreCard Corporation Schedules Third Quarter 2022 Earnings Release and Conference Call

NORCROSS, Ga., Oct. 19, 2022 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, intends to hold an investor conference call on November 2, 2022, at 11:00 A.M. Eastern Time in conjunction with the company’s earnings release for the quarter ended September 30, 2022. The company plans to issue a press release with the financial results for the period before the market opens on November 2, 2022.

Interested investors are invited to attend the conference call by accessing the webcast at https://www.webcast-eqs.com/corecard11022022_q32022_en/en or by dialing 1-877-407-0890. As part of the conference call CoreCard will be conducting a question-and-answer session where participants are invited to email their questions to [email protected] prior to the call. A transcript of the call will be posted on the company’s website at investors.corecard.com as soon as available after the call.

About CoreCard Corporation

CoreCard Corporation (NYSE: CCRD) provides a pioneering card management platform built for the future of global transactions in a digital world. Dedicated to continual technological innovation in the ever-evolving payments industry backed by decades of deep expertise in credit card offerings, CoreCard helps customers conceptualize, implement, and manage all aspects of their issuing card programs. Keenly focused on steady, sustainable growth, CoreCard has earned the trust of some of the largest companies and financial institutions in the world, providing truly real-time transactions via their proven, reliable platform operating on private on-premise and leading cloud technology infrastructure.

Forward-Looking Statements

The forward-looking statements in this press release are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company’s actual results could differ materially from those indicated by the forward-looking statements because of various risks and uncertainties including those listed in Item 1A of the Company’s Annual Report on Form 10-K and in the Company’s other filings and reports with the Securities and Exchange Commission. All of the risks and uncertainties are beyond the ability of the Company to control, and in many cases, the Company cannot predict the risks and uncertainties that could cause its actual results to differ materially from those indicated by the forward-looking statements. When used in this press release, the words “believes,” “plans,” “expects,” “will,” “intends,” “continue,” “outlook,” “progressing,” and “anticipates” and similar expressions as they relate to the Company or its management are intended to identify forward-looking statements. Except as required by law, the Company is not obligated to publicly release any revisions to these forward-looking statements to reflect the events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events
.

Investor Contact: [email protected]



SRAX to Host Business Update Conference Call on Monday, October 24th, 2022

LOS ANGELES, Oct. 19, 2022 (GLOBE NEWSWIRE) — SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, will provide a business update on Monday, October 24, 2022.

SRAX’s Founder and CEO Christopher Miglino, and CFO Michael Malone will provide an update on their current fillings with a question and answer session, on Monday, October 24th, at 11:30 am ET / 8:30 am PT.

To register for the live webcast and view the presentation, please sign up here:


https://audience.mysequire.com/webinar-view?webinar_id=281350a1-6e81-4de2-80e7-c26eb637292f

To access the conference by phone:

Dial-in:
+1 7193594580

Meeting ID:
96043795441

Passcode:
654997

About SRAX

SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.

Cautionary Statement Regarding Forward-Looking Information:

This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in our business, and our need for future capital. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in SRAX’s periodic reports filed with the SEC, including its Annual Report on Form 10-K for the year ended Dec. 31, 2020, its Quarterly Reports on Form 10-Q and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.



Kaplan Educational Foundation Honors Dr. Jesse Jackson and Dr. Nancy Lee Sánchez-Badillo for Commitment to Inclusivity and Student Success

Kaplan Educational Foundation Honors Dr. Jesse Jackson and Dr. Nancy Lee Sánchez-Badillo for Commitment to Inclusivity and Student Success

Head of Product for Firmwide Employee Experience for Integrated Help at JPMorgan Chase & Co. and Past Executive Director of the Kaplan Educational Foundation will be honored at gala event in New York City on Wednesday, October 26th

NEW YORK–(BUSINESS WIRE)–
The Kaplan Educational Foundation (KEF), which seeks to eliminate barriers to higher education for overlooked and underserved community college students and develop them as leaders for the American workforce and their communities, will present its 2022 Leadership Award to Dr. Jesse Jackson and Dr. Nancy Lee Sánchez-Badillo.

Jackson and Sánchez-Badillo will accept the Leadership Award at the Foundation’s annual benefit on October 26th in New York City. The Award recognizes lifelong commitment to inclusivity and diversity, as well as impact on enhancing academic excellence and promoting student access and success by strengthening resources around the whole student experience.

As Head of Product for Firmwide Employee Experience for Integrated Help at JPMorgan Chase & Co., Dr. Jackson oversees the global management and strategy development of this function, which focuses on modernization and improvement of the employee experience. This globally distributed high impact Integrated Help team supports more than 270,000 bank employees and retirees worldwide in addition to providing direct engagement to strategic vendors. He currently serves as the Co-Chair to BOLD (Black Organization for Leadership Development) Business Resource Group. Dr. Jackson has been with the firm for over 25 years, joining the bank via the firm’s Management Development Program after completing five years of active duty in the United States Navy. He has held other global roles including firmwide head of Learning and Career Experience for JPMorgan Chase plus several national leadership roles within both Commercial Banking and Business Banking, serving as Client Service Executive for both lines of business.

In addition to his work at JPMorgan Chase, Dr. Jackson continues to champion diversity and inclusion through his efforts as a Brooklyn International High School Teaching Entrepreneurship Reviewer and works with students to help develop business efforts in urban markets. He is also a recipient of the YMCA Black Achievers in Industry Award.

Dr. Sánchez-Badillo has over 22 years of experience providing greater access to higher education, improving the college experience, and fostering leadership among low-income, underrepresented and non-traditional students through collaborative partnerships and services that directly target factors affecting degree-attainment gaps. As the founding Director of Academic Advisement and Student Development for the Kaplan Educational Foundation, Dr. Sánchez-Badillo was responsible for the design and implementation of the Kaplan Leadership Program (KLP) model. KLP’s community college to four-year program model focuses on developing the whole student while preparing them for a lifetime of personal, financial, and socially conscious professional leadership. In 2015, she took over the Kaplan Educational Foundation and continued to develop a track record of success, with scholars earning an 85% transfer rate, and an 89% bachelor’s degree completion rate.

A 2014 National Hispanic Executive Leadership Fellow, Dr. Sánchez-Badillo completed an Executive Leadership Program at Harvard University’s John F. Kennedy School of Government and a Leadership Development Program at the Center for Creative Leadership. She is currently the Chief Opportunity Officer at Phi Theta Kappa Honor Society and continues to serve as a member of the Kaplan Educational Foundation Board of Directors and a strategic partner.

“Dr. Jackson and Dr. Sánchez-Badillo have been committed to expanding educational access and developing students from diverse backgrounds,” said Melissa Mack, Chairman of the Foundation and Chief Communications & HR Officer at global educational services company Kaplan, Inc. “Their leadership is an example for all of us working to eliminate barriers for our country’s next generation of high achievers and future leaders.”

It is beyond an honor to be recognized by an organization of the caliber of the Kaplan Educational Foundation due to its hard work and commitment to educational and economic equality,” said Dr. Jackson. “The work of the Kaplan Educational Foundation is central to uplifting our communities and building a more equitable and accessible economy for all through its investments in high-quality career-focused education programs.

“There is no greater honor than to be recognized by an organization that affirms that the talent, intellect, leadership, and compassion that resides in marginalized communities deserves recognition, investment, and development,” said Dr. Sánchez-Badillo. “KEF has reiterated that given the opportunity, they can excel in the most competitive environments and lead in their communities and professions. I am proud beyond words.”

KEF is an independent 501(c)(3) public charity, and through the Kaplan Leadership Program helps high-potential, low-income and underrepresented community college students complete their associate degree, successfully transfer and go on to earn a four-year bachelor’s degree at the nation’s most highly-selective schools. The program focuses on a holistic approach – providing extensive tutoring, academic advisement services, leadership and career training, stipends for living expenses and other resources and support to help them expand their personal goals, and eventually attain leadership roles in their professions and communities.

Since its inception in 2006, the Kaplan Leadership Program has helped more than 100 Scholars gain admission to the country’s most competitive schools, including Yale, Stanford, Brown, Princeton, Amherst, Cornell, Mount Holyoke, Smith and many others. Eighty-seven percent of KLP scholars earn a bachelor’s degree. Today, Scholars are practicing law and medicine, conducting scientific research, serving in business, education and engineering, and leading in government, and public and private industries.

The 2022 Annual Benefit celebrates KEF’s 16th year of removing obstacles to higher education and serves as the organization’s chief fundraising event. To attend or sponsor the event, please click here.

If you are interested in attending the event as a member of the media, please contact Valerie Silverman Kerr at[email protected].

ABOUT THE KAPLAN EDUCATIONAL FOUNDATION

The Kaplan Educational Foundation, a 501 3(c) nonprofit public charity, was initially established and supported by a generous endowment funded by Kaplan, Inc. executives with the idea of helping a small group of students in a big way. The Foundation provides high-potential, low-income students with academic and financial support and leadership training to raise their expectations for success and open doors to opportunities that will change their lives and communities. For more information, please visit www.kaplanedfoundation.org.

ABOUT KAPLAN, INC.

Kaplan, Inc. is a global educational services company that helps individuals and institutions advance their goals in an ever-changing world. Our broad portfolio of solutions help students and professionals advance their education and careers, universities and educational institutions attract and support students, and businesses maximize employee recruitment, development, and advancement. Stanley Kaplan founded our company in 1938 with a mission to expand educational opportunities for students of all backgrounds. Today, thousands of Kaplan employees in 27 countries continue Stanley’s mission, working with students and professionals and 12,000 corporate and 4,000 school and university clients worldwide. Kaplan is a subsidiary of Graham Holdings Company (NYSE: GHC). Learn more at www.kaplan.com.

Press:

Valerie Silverman Kerr

VSK Public Relations, LLC

914-806-6647

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Philanthropy DEI (Diversity, Equity and Inclusion) Other Education Training University Other Philanthropy Foundation Education

MEDIA:

Logo
Logo

Piedmont Lithium Selected for $141.7 Million Grant by United States Department of Energy for Tennessee Lithium Project

Piedmont Lithium Selected for $141.7 Million Grant by United States Department of Energy for Tennessee Lithium Project

Selection underscores the key role Piedmont Lithium will have in boosting domestic lithium hydroxide supply

BELMONT, N.C.–(BUSINESS WIRE)–Piedmont Lithium (“Piedmont”, “Company”) (Nasdaq: PLL; ASX: PLL), a leading global developer of lithium resources critical to the U.S. electric vehicle (“EV”) supply chain, today announced that it has been selected for a $141.7 million grant from the U.S. Department of Energy (“DOE”) – one of the first set of projects funded by the President’s Bipartisan Infrastructure Law to expand domestic manufacturing of batteries for EVs and the electrical grid and for materials and components currently imported from other countries. The funding will support the construction of the Company’s approximately $600 million Tennessee Lithium project, which aims to expand the U.S. supply of lithium hydroxide by 30,000 metric tons per year (“tpy”). Lithium hydroxide is a key component of high energy density, long-range, electric vehicle batteries.

Piedmont President and CEO Keith Phillips said the Company is honored that the Tennessee Lithium project has been selected for this DOE funding. “The U.S. government is putting investment dollars behind its policies to support energy independence and national security, and we are grateful to be selected to help spur critical, domestic development of the EV battery supply chain,” said Phillips. “Over 80% of lithium hydroxide production today occurs in China. This grant will accelerate the development of the Tennessee Lithium project as a world-class lithium hydroxide operation, which is expected to more than double the domestic production of battery-grade lithium hydroxide in the United States.”

Located in Etowah in McMinn County, Tennessee, Piedmont’s Tennessee Lithium project is being designed to produce lithium hydroxide from spodumene concentrate using the innovative Metso:Outotec process flow sheet, enabling lower emissions and carbon intensity as well as improved capital and operating costs relative to incumbent operations. The Tennessee Lithium project is expected to drive significant economic activity in McMinn County and create approximately 120 new, direct jobs.

“We are pleased that the DOE has chosen to support our Tennessee Lithium project, and we are committed to being responsible stewards of these grant funds,” said Piedmont Chief Operating Officer Patrick Brindle. “This funding will enable us to accelerate detailed engineering and place orders for long-lead items.” Construction at the Tennessee Lithium project is slated to begin in 2023, subject to permitting and project financing timelines, with production expected to commence in 2025.

As part of the Company’s selection for this DOE funding, Piedmont has been invited to negotiate the specific terms of the grant, including timing and any co-funding. The final details of the project grant are subject to these negotiations. The grant will not be final until Piedmont and the DOE have agreed to the specific terms of the grant. Once the terms have been finalized, funding of the grant will remain subject to satisfaction from time to time of conditions precedent set forth in those terms.

When the Company’s current portfolio of lithium assets becomes fully operational, Piedmont expects to produce 60,000 tpy of lithium hydroxide in the United States, where current domestic production is only approximately 15,000 tpy. Piedmont’s estimated production should position the Company to serve the growing U.S. battery manufacturing industry, which has made announcements of capital investments exceeding $50 billion for new U.S. battery plants. These battery plants are expected to require more than 600,000 tpy of lithium hydroxide.

The Tennessee Lithium project is a core project in Piedmont’s development plans, with the Company anticipating production to come online on the following schedule:

  • 2023: Quebec – spodumene concentrate production at North American Lithium
  • 2024: Ghana – spodumene concentrate production at Ewoyaa
  • 2025: Tennessee Lithium – lithium hydroxide production from spodumene concentrate sourced from our international investments
  • 2026: Carolina Lithium – integrated spodumene concentrate and lithium hydroxide production

About Piedmont Lithium

Piedmont Lithium (Nasdaq: PLL; ASX: PLL) is developing a world-class, multi-asset, integrated lithium business focused on enabling the transition to a net zero world and the creation of a clean energy economy in North America. Our goal is to become one of the largest lithium hydroxide producers in North America by processing spodumene concentrate produced from assets where we hold an economic interest. Our projects include our wholly-owned Carolina Lithium and Tennessee Lithium projects in the United States and partnerships in Quebec with Sayona Mining (ASX:SYA) and in Ghana with Atlantic Lithium (AIM:ALL). These geographically diversified operations will enable us to play a pivotal role in supporting America’s move toward decarbonization and the electrification of transportation and energy storage. For more information, visit www.piedmontlithium.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of or as described in securities legislation in the United States and Australia, including statements regarding exploration, development, and construction activities of Sayona Mining Limited, Atlantic Lithium Limited, and Piedmont; current plans for Piedmont’s mineral and chemical processing projects; and strategy. Such forward-looking statements involve substantial and known and unknown risks, uncertainties, and other risk factors, many of which are beyond our control, and which may cause actual timing of events, results, performance or achievements and other factors to be materially different from the future timing of events, results, performance, or achievements expressed or implied by the forward-looking statements. Such risk factors include, among others: (i) that Piedmont, Sayona Mining, or Atlantic Lithium will be unable to commercially extract mineral deposits, (ii) that Piedmont’s, Sayona Mining’s, or Atlantic Lithium’s properties may not contain expected reserves, (iii) risks and hazards inherent in the mining business (including risks inherent in exploring, developing, constructing and operating mining projects, environmental hazards, industrial accidents, weather or geologically related conditions), (iv) uncertainty about Piedmont’s ability to obtain required capital to execute its business plan, (v) Piedmont’s ability to hire and retain required personnel, (vi) changes in the market prices of lithium and lithium products, (vii) changes in technology or the development of substitute products, (viii) the uncertainties inherent in exploratory, developmental and production activities, including risks relating to permitting, zoning and regulatory delays related to our projects as well as the projects of our partners in Quebec and Ghana, (ix) uncertainties inherent in the estimation of lithium resources, (x) risks related to competition, (xi) risks related to the information, data and projections related to Sayona Quebec, Sayona Mining, and Atlantic Lithium, (xii) occurrences and outcomes of claims, litigation and regulatory actions, investigations and proceedings, (xiii) risks regarding our ability to achieve profitability, enter into and deliver product under supply agreements on favorable terms, our ability to obtain sufficient financing to develop and construct our projects, our ability to comply with governmental regulations and our ability to obtain necessary permits, (xiv) uncertainties related to the negotiation, execution and funding of DOE grants, including our ability to successfully negotiate the grant terms and to satisfy any funding conditions under the award and (xv) other uncertainties and risk factors set out in filings made from time to time with the U.S. Securities and Exchange Commission (“SEC”) and the Australian Securities Exchange, including Piedmont’s most recent filings with the SEC. The forward-looking statements, projections and estimates are given only as of the date of this press release and actual events, results, performance, and achievements could vary significantly from the forward-looking statements, projections and estimates presented in this press release. Readers are cautioned not to put undue reliance on forward-looking statements. Piedmont disclaims any intent or obligation to update publicly such forward-looking statements, projections, and estimates, whether as a result of new information, future events or otherwise. Additionally, Piedmont, except as required by applicable law, undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of Piedmont, its financial or operating results or its securities.

Erin Sanders

VP, Corporate Communications

T: +1 704 575 2549

E: [email protected]

Christian Healy/Jeff Siegel

Media Inquiries

E: [email protected]

E: [email protected]

KEYWORDS: Tennessee Ireland Australia/Oceania United States United Kingdom North America Australia Europe

INDUSTRY KEYWORDS: General Automotive EV/Electric Vehicles Automotive Other Construction & Property Public Policy/Government Alternative Energy Energy Commercial Building & Real Estate Construction & Property Environment Mining/Minerals Sustainability White House/Federal Government Natural Resources

MEDIA:

Logo
Logo